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Abstract We examined whether a proposed spatial proximity
between Asp114(2.50) and Asn332(7.49) affected the func-
tional properties of the W opioid receptor. The D114(2.50)N
mutant had reduced binding affinities for morphine, DAMGO
and CTAP, but not for naloxone and [3H]diprenorphine; this
mutation also abolished agonist-induced increase in [35S]GTPQS
binding. The N332(7.49)D mutation eliminated detectable
binding of either [3H]diprenorphine or [3H]DAMGO. The
combined D114(2.50)N-N332(7.49)D mutation restored high
affinity binding for [3H]diprenorphine, CTAP and naloxone,
and restored partially the binding affinities, potencies and
efficacies of morphine and DAMGO. Thus, reciprocal mutations
of Asp114(2.50) and Asn332(7.49) compensate for the detri-
mental effects of the single mutations, indicating that the residues
are adjacent in space and that their chemical functionalities are
important for ligand binding and receptor activation.
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1. Introduction
Opiate and opioid compounds act on opioid receptors to
produce their pharmacological actions. Multiple opioid recep-
tors (W, N, U, O) have been demonstrated from pharmacolog-
ical, binding, anatomical and molecular data (for reviews, [1^
3]). These opioid receptors are coupled through G proteins to
a¡ect a variety of e¡ectors, which include adenylate cyclase,
potassium channels, calcium channels (for a review, [4]) and a
mitogen-activated protein kinase pathway (for example, [5]).
The W opioid receptors are closely associated with analgesic
and euphoric actions of opiate and opioid compounds [1].
Two splice variants of W opioid receptors have been cloned
[6^9]. Deduced amino acid sequences of these clones display
the motif of putative seven K-helical transmembrane helices
(TMHs) connected by alternating intracellular and extracellu-
lar hydrophilic loops, that is characteristic of G protein-
coupled receptors (GPCRs). The splice variants of the W
opioid receptor share the same putative TMHs with sequence
variations in the C-terminal domain.
Our current understanding of the molecular mechanisms of
GPCR functions draws on the growing information about
structural details of the receptor molecules and the relation-
ship between these structural elements and the functional
properties (for reviews, [10^15]). Although high-resolution
structures of GPCRs are not yet available, local structural
data obtained by site-directed mutagenesis and chimeric re-
ceptors have provided some insight into the mechanisms of
receptor binding and activation and the potential functional
roles of speci¢c residues and domains of receptors (for re-
views, [10,13^15]). A feature common to GPCRs is a network
of side-chain interactions among TMHs that maintain the
structural integrity and underlie receptor activation. Residues
that are highly conserved among GPCRs are likely to be
essential structural determinants of receptors and to play a
role in their functions. An Asp in TMH 2 (Asp2.50 in the
generic nomenclature, see Section 2) and an Asn in TMH 7
(Asn7.49 in the generic nomenclature) are conserved in the
same positions of the putative TMHs in over 95% of GPCRs
[16]. The role of the conserved Asp2.50 has been examined in
many GPCRs. Mutation of this Asp has been shown to a¡ect
agonist a⁄nity, G protein coupling, sensitivity to Na or
guanine nucleotides (for a review, [10]). In the 5-HT2A recep-
tor, mutation of this Asp in TMH 2 to Asn abolished sero-
tonin-induced increase in IP3 generation. However, an addi-
tional mutation of the Asn in TMH 7 to Asp (N7.49D)
partially restored the receptor function, indicating that
Asp2.50 and Asn7.49 are in close proximity and likely to
interact by hydrogen bonding [17]. The corresponding resi-
dues are reversed in the wild-type gonadotropin-releasing hor-
mone (GnRH) receptor, which has an Asn in TMH 2 and an
Asp in TMH 7. Nevertheless, the same restoration of function
was observed from reciprocal mutations of these residues, in-
dicating a spatial proximity and potential for interactions sim-
ilar to that demonstrated for the 5-HT2A serotonin receptor
[18].
Not much is known about the relative proximity of these
two loci in opioid receptors. Surratt et al. [19] demonstrated
that Asp114(2.50) of the W opioid receptor was important for
high a⁄nity agonist binding and receptor activation. In the
present study, we examined by site-directed mutagenesis stud-
ies in the rat W opioid receptors the possible interactions be-
tween Asp114(2.50) and Asn332(7.49) and their functional
consequences. Binding a⁄nities of morphine (non-peptide ag-
onist), DAMGO (peptide agonist), naloxone (non-peptide an-
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tagonist) and CTAP (peptide antagonist) were determined by
competitive inhibition of [3H]diprenorphine binding. Mor-
phine- and DAMGO-induced increase in [35S]GTPQS binding
was used as the functional measure of receptor activation for
the various constructs.
2. Materials and methods
2.1. Materials
[3H]diprenophine (58 Ci/mmole), [3H]DAMGO (54 Ci/mmole) and
[35S]GTPQS (1000^1200 Ci/mmole) were purchased from NEN Life
Science (Boston, MA, USA). Morphine was provided by the National
Institute on Drug Abuse. Naloxone was a gift from DuPont/Merck
Co. (Wilmington, DE, USA). Muta-Gene kit was purchased from
Bio-Rad Co. (Hercules, CA, USA); DAMGO and CTAP from Phoe-
nix Pharmaceuticals, Inc. (Mountain View, CA, USA); Lipofectamine
from GIBCO-BRL (Gaitherburg, MD, USA); Vectastain ABC kit
from Vector Laboratories (Burlingame, CA, USA); the mouse mono-
clonal antibody (clone 12CA5) against hemagglutinin (HA) and HA
peptide from Boehringer Mannheim Co. (Indianapolis, IN, USA);
GDP, GTPQS, geneticin, 3,3P-diaminobenzidine tetrahydrochloride
and hydrogen peroxide were from Sigma.
2.2. Numbering schemes for amino acid residues in the W opioid receptor
Two numbering schemes were used. Amino acid residues in the W
opioid receptor were identi¢ed by their sequence numbers. In addi-
tion, the generic numbering scheme of amino acid residues in GPCRs
proposed by Ballesteros and Weinstein [15] was used. According to
this nomenclature, amino acid residues in putative TMHs are assigned
two numbers (N1, N2). N1 refers to the TMH number. For N2, the
most conserved residue in each TMH is assigned 50, and the other
residues are numbered in relation to this conserved residue, with
numbers decreasing towards the N-terminus and increasing toward
the C-terminus. In TMH 2 of the W opioid receptor, Asp114 corre-
sponds to the most conserved residue and hence is assigned the index
2.50. The residue is referred to as Asp114(2.50) to enable a structural
comparison to the equivalent positions in other GPCRs. The Asn332
of this receptor precedes the most conserved residues in TMH 7,
which is Pro333, and hence is identi¢ed as Asn332(7.49). The generic
numbering allows for cross-reference to the published literature on
other GPCRs.
2.3. Oligodeoxynucleotide-directed mutagenesis
Mutations were introduced into the rat W receptor [6] with the uracil
replacement method of Kunkel [20] using the Muta-Gene kit. Mutants
were selected by DNA sequence determination with the method of
Sanger et al. [21]. Mutant W receptors were subcloned into the HindIII
site of the mammalian expression vector pcDNA3. Correctly oriented
clones were used for subsequent studies.
2.4. Transient expression of the wild-type and mutant W receptors
in CHO cells
CHO cells were transfected with the rat wild-type or mutant W
receptor cDNA with Lipofectamine [22] according to the manufactur-
er’s instructions.
2.5. Stable expression of the wild-type and mutant W receptors in
CHO cells
CHO cell lines stably expressing the cloned rat W receptor or its
mutant were established as described previously [23]. CHO cells ex-
pressing similar levels of the wild-type, D114(2.50)N and
D114(2.50)N-N332(7.49)D W receptors (V0.8 pmole/mg membrane
protein) were used in the present study.
2.6. Opioid receptor binding
Membranes were prepared from CHO cells and opioid receptor
binding was performed with [3H]diprenorphine according to our pub-
lished procedure [24]. Binding was carried out in 50 mM Tris-HCl
bu¡er containing 1 mM EGTA and 4 WM leupeptin (pH 7.4) (TEL
bu¡er), unless indicated otherwise, at room temperature for 1 h.
[3H]diprenorphine saturation binding was performed for determina-
tion of Kd and Bmax values. Competitive inhibition of [3H]dipre-
norphine binding by drugs was performed with [3H]diprenorphine at
a concentration close to its Kd value. Naloxone (1 WM) was used to
de¢ne non-speci¢c binding. Binding data were analyzed with the
EBDA program [25].
2.7. Agonist-induced increase in [35S]GTPQS binding
Determination of [35S]GTPQS binding to G proteins was carried
out with our published procedure [26]. EC50 and maximal response
values were calculated by use of the equation y = Emax/[1+(x/EC50)s]+
background, where y is the response at the dose x, Emax is the max-
imal response and s is a slope factor. The KB value of an antagonist
was calculated by use of the equation [AP]/[A] = [B]/KB+1, where [AP]
and [A] were the concentration of an agonist which produced an equal
response in the presence and absence of the concentration of the
antagonist [B] [27].
2.8. Determination of protein content
Protein contents of membranes were determined by the bicincho-
ninic acid method of Smith et al. [28] with bovine serum albumin as
the standard.
2.9. Epitope tagging of the wild-type and N332(7.49)D rat W opioid
receptor with HA
HA sequence (YPYDVPDYA) was inserted into the receptor im-
mediately after the ¢rst methionine residue by polymerase chain re-
action [29]. HA-tagged receptors were cloned into the HindIII site of
the vector pcDNA3. DNA sequence was determined with the method
of Sanger et al. [21] to con¢rm the correct insertion of the HA se-
quence and the absence of unwanted mutations.
2.10. Immunocytochemical studies
CHO cells were transfected with the HA-tagged rat wild-type or
N332(7.49)D mutant W receptor cDNAs or empty vector with Lipo-
fectamine. Cells were plated on the Lab-Tek chamber slide 36^48 h
after transfection, grown for one day, gently washed, ¢xed with 4%
paraformaldehyde in 0.1 M phosphate bu¡er (pH 7.0) at 4‡C for 1 h,
and washed again to remove the ¢xative. Immunohistochemistry was
performed with the avidin-biotin-peroxidase method according to a
published procedure [30]. Fixed cells were incubated with the mouse
monoclonal antibody against HA (clone 12CA5) diluted 1:5000 at
4‡C for 16^24 h followed by incubation with biotinylated horse
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Table 1
Kd and Bmax values of [3H]diprenorphine binding to the wild-type, D114(2.50)N, N332(7.49)D and D114(2.50)N-N332(7.49)D W opioid receptor
constructs expressed in CHO cells
W Opioid receptor construct Transmembrane helix [3H]diprenorphine binding
2 7 Kd (nM) Bmax (pmol/mg protein)
Wild-type D N 0.03 þ 0.002 0.87 þ 0.08
D114(2.50)N N N 0.12 þ 0.02 0.99 þ 0.06
N332(7.49)D D D ud ud
D114(2.50)N-N332(7.49)D N D 0.05 þ 0.009 0.78 þ 0.08
The wild-type and the mutant W opioid receptors were transfected into CHO cells and clonal cell lines stably expressing each receptor were
established. Saturation binding of [3H]diprenorphine to the wild-type, D114(2.50)N, N332(7.49)D and D114(2.50)N-N332(7.49)D W opioid recep-
tors were performed and Kd and Bmax values were calculated as described in Section 2. Each value represents the mean þ S.E.M. of three to ¢ve
independent experiments in duplicate.
Ud, binding was undetectable in CHO cells transiently transfected with the N332(7.49)D mutant W receptor.
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anti-mouse Ig G (1:200) at room temperature for 45 min. Subse-
quently cells were incubated with avidin-biotin-peroxidase complex
for 45 min and reacted with 3,3P-diaminobenzidine tetrahydrochloride
(0.006%) and hydrogen peroxide (0.0018%) for 3^6 min. Between in-
cubations, cells were washed three times with 10 mM phosphate bu¡er
(pH 7.4), 1% normal horse serum and 0.1% NP-40 at room temper-
ature. Two types of controls were performed: incubation with anti-
body preincubated with HA peptide (10 Wg/ml) and cells transfected
with the vector alone. Cells were dehydrated through 70, 95, and
100% ethanol, cleared with xylene and coverslipped with Permount.
The cells were then examined using bright-¢eld and phase-contrast
microscopy. The deep brown reaction product indicates the presence
of HA-tagged receptor.
3. Results
3.1. E¡ects of D114(2.50)N, N332(7.49)D and
D114(2.50)N-N332(7.49)D mutations on ligand binding
a⁄nities
The wild-type and D114(2.50)N, N332(7.49)D and
D114(2.50)N-N332(7.49)D mutant W opioid receptors were
¢rst transiently transfected into CHO cells and
[3H]diprenorphine binding was examined. While the wild-
type and D114(2.50)N and D114(2.50)N-N332(7.49)D mu-
tants had robust binding, the N332(7.49)D mutant did not.
The N332(7.49)D mutant also did not exhibit binding for
[3H]DAMGO.
The wild-type and D114(2.50)N and D114(2.50)N-
N332(7.49)D mutants were stably transfected into CHO cells
and clonal cell lines established. Saturation [3H]diprenorphine
binding was performed and cell lines with similar receptor
expression levels (V0.8 pmole/mg protein) were used for the
study. Table 1 shows Kd and Bmax values of [3H]diprenorphine
binding to the wild-type, D114(2.50)N and D114(2.50)N-
N332(7.49)D W receptors. Both D114(2.50)N and
D114(2.50)N-N332(7.49)D mutants retained high a⁄nity
[3H]diprenorphine binding.
We then determined whether the lack of binding to the
N332(7.49)D mutant was due to poor expression. Both the
wild-type and N332(7.49)D W receptors were tagged with
HA. When transiently expressed in CHO cells, the HA-tagged
wild-type, but not the HA-tagged N332(7.49)D mutant, ex-
hibited high levels of [3H]diprenorphine binding. Immunohis-
tochemistry of CHO cells transiently transfected with HA-
tagged N332(7.49)D mutant using anti-HA monoclonal anti-
body showed intense staining, similar to the HA-tagged wild-
type receptor (Fig. 1), indicating that the N332(7.49)D mutant
is expressed. At light microscopy level, it is not possible to
discriminate between intracellular and membrane expression
of the receptor. Thus, the lack of binding to the N332(7.49)D
mutant is due to disruption of the binding pocket by the
N332(7.49)D mutation or to improper processing of the mu-
tant receptor protein.
Ki values of four ligands (DAMGO, morphine, CTAP and
naloxone) in inhibiting [3H]diprenorphine binding are shown
in Table 2. D114(2.50)N mutation greatly reduced the a⁄n-
ities of DAMGO, morphine and CTAP with the Ki values
increased by 212-, 134- and 684-fold, respectively, compared
with those of the wild-type. However, the same mutation af-
fected the a⁄nity of naloxone only slightly. Remarkably, the
combined D114(2.50)N-N332(7.49)D mutant retained high af-
¢nity binding for CTAP, with the Ki value similar to that of
the wild-type W receptor. In addition, binding a⁄nities of
morphine and DAMGO, which were lowered dramatically
by the D114(2.50)N mutation, were restored partially by the
combined D114(2.50)N-N332(7.49)D mutation.
3.2. E¡ects of D114(2.50)N and D114(2.50)N-N332(7.49)D
mutations on W receptor activation by morphine and
DAMGO
The D114(2.50)N mutation essentially abolished agonist ac-
tivities of morphine and DAMGO in increasing [35S]GTPQS
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Table 3
Agonist-stimulated [35S]GTPQS binding to membranes: EC50 values and maximal e¡ects of morphine and DAMGO in activating the wild-type
and D114(2.50)N, N332(7.49)D and D114(2.50)N-N332(7.49)D mutant W opioid receptors
Agonist W Opioid receptor construct EC50 (nM) Maximal stimulated binding
(fmol/mg protein) (% of wild-type)
Morphine Wild-type 81.0 þ 4.6 109 þ 10 100
D114(2.50)N nd 2.3 þ 0.4 2.1
D114(2.50)N-N332(7.49)D 328 þ 19 60.7 þ 4.0 55.8
DAMGO Wild-type 59.5 þ 10.8 152 þ 20 100
D114(2.50)N nd 8.9 þ 2.2 5.9
D114(2.50)N-N332(7.49)D 197 þ 10 86.5 þ 1.2 57.0
Activation of the wild-type, D114(2.50)N, N332(7.49)D and D114(2.50)N-N332(7.49)D mutant W opioid receptors by morphine or DAMGO to
increase [35S]GTPQS binding was determined as described in Section 2. Each value is the mean þ S.E.M. of three independent experiments in
duplicate.
Nd, can not be determined.
Table 2
Ki values (nM) of DAMGO, morphine, CTAP and naloxone in inhibiting [3H]diprenorphine binding to the wild-type, D114(2.50)N and
D114(2.50)N-N332(7.49)D W receptors
Ligand Wild-type D114(2.50)N Fold change
[D114(2.50)N/wt]
D114(2.50)N-N332(7.49)D Fold change
[D114(2.50)N-N332(7.49)D/wt]
DAMGO 1.4 þ 0.3 296 þ 52 (212) 61.1 þ 23.2 (44)
Morphine 5.1 þ 1.5 684 þ 115 (134) 192 þ 54 (38)
CTAP 0.0057 þ 0.0006 3.9 þ 1.8 (684) 0.0066 þ 0.0029 (1.2)
Naloxone 0.7 þ 0.1 1.1 þ 0.1 (1.6) 0.9 þ 0.2 (1.3)
Inhibition of [3H]diprenorphine binding by each ligand to the wild-type and the mutant W opioid receptors was performed and Ki values were
determined as described in Section 2. Each value is the mean þ S.E.M. of three to ¢ve independent experiments in duplicate. Wt, wild-type.
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binding (Table 3). In contrast, the potencies and e⁄cacies of
morphine and DAMGO in enhancing [35S]GTPQS binding
were partially retained in the D114(2.50)N-N332(7.49)D mu-
tant (Table 3). EC50 values of morphine and DAMGO were
only 4- and 3.3-fold higher than in the wild-type and the
maximal responses were 56% and 57% of those of the wild-
type, respectively.
3.3. Potencies of the antagonists naloxone and CTAP at the
wild-type and D114(2.50)N-N332(7.49)D mutant W
receptors
KB values were determined for naloxone and CTAP in an-
tagonizing DAMGO activation of the wild-type and
D114(2.50)N-N332(7.49)D mutant W receptors (Table 4).
The D114(2.50)N-N332(7.49)D mutation did not a¡ect the
potency of either antagonist.
3.4. GTP shift of DAMGO binding a⁄nities to the wild-type,
D114(2.50)N and D114(2.50)N-N332(7.49)D W opioid
receptors
Multiple agonist a⁄nity states of opioid receptors and other
GPCRs were reported to represent various G protein-associ-
ated and dissociated states [31]. While high a⁄nity states rep-
resent G protein-coupled states, low a⁄nity states represent
conformations that are uncoupled from G proteins or associ-
ated with G proteins with less e⁄ciency. Competitive inhibi-
tion of [3H]diprenorphine binding by DAMGO was con-
ducted in the presence of 100 mM NaCl, 5 mM MgCl2 and
30 WM GTPQS, which has been shown to uncouple receptors
from G proteins and convert all receptors to a low a⁄nity
state for agonists [32,33]. The presence of NaCl, MgCl2 and
GTPQS decreased the a⁄nity of DAMGO for the wild-type by
46-fold; however, it had no e¡ect on the Ki value of DAMGO
for the D114(2.50)N mutant and increased its Ki value for the
D114(2.50)N-N332(7.49)D mutant only by 1.9-fold (Table 5).
These results indicate that while the wild-type receptor is
tightly pre-coupled to G proteins, the D114(2.50)N mutant
is uncoupled from G protein and the revertant
D114(2.50)N-N332(7.49)D mutant is weakly pre-coupled to
G protein.
4. Discussion
If two residues play independent roles in a certain property
of the receptor, their simultaneous mutation is expected to
have additive e¡ects. This is not the case for residues
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Table 4
Potencies of naloxone and CTAP in antagonizing activation of the
wild-type and D114(2.50)N-N332(7.49)D mutant W opioid receptors
by DAMGO
Antagonist W Opioid receptor construct KB (nM)
Naloxone Wild-type 0.94 þ 0.12
D114(2.50)N-N332(7.49)D 1.2 þ 0.18
CTAP Wild-type 0.009 þ 0.002
D114(2.50)N-N332(7.49)D 0.014 þ 0.004
Dose-response of DAMGO-induced increase in [35S]GTPQS binding
to membranes of CHO cells stably transfected with the wild-type or
D114(2.50)N-N332(7.49)D mutant W opioid receptor was performed
in the presence or absence of 10 nM naloxone or 0.1 nM CTAP and
KB values were determined as described in Section 2. Each value
represents the mean þ S.E.M. of three to four independent determina-
tions in duplicate.
Fig. 1. Immunohistochemical staining of HA-tagged wild-type (A) and N332(7.49)D (C) W opioid receptors transiently expressed in CHO cells
with the 12CA5 monoclonal antibody against HA. Controls were performed with CHO cells transfected with the expression vector or antibody
pre-absorbed with the HA peptide (B, wild-type; D, N332(7.49)D). Magni¢cation is 800U for each. The experiments were conducted three
times with the same results.
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Asp114(2.50) and Asn332(7.49) in the rat W opioid receptor.
We found that the D114(2.50)N mutation reduced binding
a⁄nities, potencies and e⁄cacies of DAMGO and morphine
as well as the binding a⁄nity of CTAP, while the
N332(7.49)D mutation eliminated [3H]diprenorphine and
[3H]DAMGO binding. However, the combination of
D114(2.50)N and N332(7.49)D mutations was not detrimen-
tally additive, but rather restored binding a⁄nity of CTAP
and partially restored the binding a⁄nities, potencies and e⁄-
cacies of DAMGO and morphine. The non-additivity of their
e¡ects indicates that Asp114(2.50) and Asn332(7.49) are not
independent of each other, and because they seem to be nearly
interchangeable, they are likely to share the same microenvi-
ronment. This observation is similar to those on 5-HT2A re-
ceptor [17] and GnRH receptor [18]. By pharmacological
studies and computational simulations, Zhou et al. [18] and
Sealfon et al. [17] showed that TMH 2 and TMH 7 are ad-
jacent in space and likely to form hydrogen bonds between
Asp and Asn in GnRH receptor and 5-HT2A receptor. Our
results suggest a similar interaction between Asp114(2.50) and
Asn332(7.49) in the W opioid receptor. The fact that reversal
of chemical functionalities at these two loci restores activities
lost upon single mutations further indicates that they have a
joint role in the underlying mechanisms. Such a role has been
suggested recently [34].
Notably, the wild-type and D114(2.50)N-N332(7.49)D mu-
tant W opioid receptors share some pharmacological properties
and di¡er in others. Thus, the antagonists naloxone and
CTAP had similarly high binding a⁄nities and were similarly
potent as antagonists at both receptors. However, the agonists
morphine and DAMGO exhibited lower a⁄nities, potencies
and e⁄cacies at the D114(2.50)N-N332(7.49)D mutant than
the wild-type. In addition, the presence of Mg2, Na and
GTPQS reduced DAMGO a⁄nity for the wild-type much
more profoundly than they did for the D114(2.50)N-
N332(7.49)D mutant. These di¡erences in agonist binding
and G protein coupling indicate that the Asp114 at position
2.50 in TMH 2 and Asn332 at position 7.49 in TMH 7 are not
entirely interchangeable in their functions, suggesting that
these two residues are part of a more complex network with
other loci. Based on molecular dynamics simulation of con-
stitutively active K1B-adrenergic receptor, Scheer et al. [35,36]
identi¢ed a conserved polar pocket near the cytosolic interface
formed by a network of hydrogen bonds among the conserved
residues Asn63(1.50), Asp91(2.50), Asn344(7.49) and
Tyr348(7.53). It was postulated [35,36] that these interactions
constrain the receptor in an inactive state and that the shift of
Arg143(3.50) in the conserved DRY sequence in TMH 3 out
of the polar pocket leads to receptor activation. More re-
cently, Ballesteros et al. [34] concluded, from mutagenesis
studies and molecular dynamics simulations on the TMH con-
taining the same DRY motif in the GnRH receptor, that the
conserved Arg at position 3.50 is constrained by an interac-
tion with the preceding Asp3.49 of DRY in the inactive form
of the GPCRs. When the GPCR is activated, the Asp at
position 3.49 becomes protonated and Arg3.50 is released to
enable its interaction with Asp2.50 and Asn7.49 (in the case of
GnRH receptor, Asn2.50 and Asp7.49). This is consistent
with the repeated ¢ndings including the present results, show-
ing that mutation of Asp2.50 to Ala or Asn eliminates or
profoundly reduces receptor activation by agonists in many
GPCRs (for reviews, [10^15]).
In the N332(7.49)D W receptor, which has an Asp in both
TMH 2 and TMH 7, ligand binding and/or receptor protein
processing are disrupted. The immunohistochemistry results
could not di¡erentiate between intracellular retention of the
receptor protein and membrane expression of a receptor with
improperly packed TMHs. Either possibility suggests a com-
plementary Asp/Asn pair in TMH 2/TMH 7 of this receptor.
Notably, the Asn332(7.49) is not likely to be directly involved
in ligand binding. This is suggested by two observations. One
is the strong conservation of an Asn or Asp at this site in
GPCRs with ligands of very diverse structures. The other is
that the D114(2.50)N-N332(7.49)D double mutant has bind-
ing a⁄nities for naloxone, diprenorphine and CTAP that are
indistinguishable from those of the wild-type. The present
¢ndings as well as data from other studies in which this locus
was mutated [17,18] indicate that Asn332(7.49) is more likely
to be involved indirectly in maintaining the integrity of the
binding pocket. In particular, the speci¢c structural property
of the Asn7.49 Pro7.50/Asp7.49 Pro7.50 motif that has been
characterized recently [37] indicates the mode in which this
structural role can be expressed.
In contrast to the N332(7.49)D mutant, the D114(2.50)N
mutant with Asn in both loci was tolerated well. High a⁄nity
binding was retained for both the antagonists naloxone and
diprenorphine, consistent with the ¢ndings of Surratt et al.
[19]. It is likely that Asn can act as both a hydrogen-bond
acceptor (C = O) and a donor (NH2) but Asp can only be an
acceptor at the O position [18]. Thus, interactions such as
hydrogen bonding in both the D114(2.50)N mutant and
D114(2.50)N-N332(7.49)D double mutant receptors may re-
tain receptor conformation to some extent. In this regard, the
W opioid receptor is similar to the GnRH receptor although
there are Asn in the TMH 2 and Asp in the TMH 7 in the
wild-type GnRH receptor. But the W receptor is di¡erent from
the 5-HT2A receptor in that the mutant 5-HT2A receptor re-
tained high a⁄nity ligand binding and G protein coupling
when Asp was present at both loci [17]. The speci¢c behaviors
of the mutant W opioid, the GnRH and the 5-HT2A receptors
are most likely due to di¡erences in the immediate environ-
ment of Asp2.50 and Asn7.49 in these particular receptors,
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Table 5
Ki values (nM) of DAMGO binding to the wild-type, D114(2.50)N and D114(2.50)N-N332(7.49)D W receptors in the presence and absence of
GTPQS
W Opioid receptor construct Ki in TEL bu¡er Ki in GTPQS bu¡er Ki (GTPQS bu¡er)/Ki (TEL bu¡er)
Wild-type 1.5 þ 0.3 69 þ 8.9 46
D114(2.50)N 279 þ 55 308 þ 52 1.1
D114(2.50)N-N332(7.49)D 59 þ 20 111 þ 13 1.9
Competitive inhibition of [3H]diprenorphine binding by DAMGO to the wild-type and the mutant W opioid receptors was performed in TEL bu¡er
or in TEL bu¡er plus 100 mM NaCl, 5 mM MgCl2 and 30 WM GTPQS (GTPQS bu¡er) as described in Section 2. Each value is the mean þ S.E.M.
of three independent experiments in duplicate.
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which di¡er in the identity of the amino acid side chains of
surrounding residues.
Our results showing that the D114(2.50)N mutation greatly
reduced the a⁄nities of DAMGO and morphine for the W
receptor and abolished the abilities of DAMGO and mor-
phine to activate the receptor are consistent with a large num-
ber of reports indicating that Asp at position 2.50 is impor-
tant for high a⁄nity agonist binding and receptor-G protein
coupling (for a review, [10]). In particular, Surratt et al. [19]
demonstrated this for the W opioid receptor. The di¡erential
e¡ects of the D114(2.50)N mutation on naloxone and dipre-
norphine vs. morphine and DAMGO suggest that these ago-
nists and antagonists may bind to di¡erent conformations of
the receptor or have di¡erent binding domains.
Recent molecular dynamics simulations of 5-HT2A receptor
models provided some insights into the role of Asp in TMH 2
in the rearrangement of receptor structure due to agonist, but
not antagonist binding. Upon activation by 5-HT, there are
signi¢cant conformational changes observed in the TMHs 5
and 6 toward the intracellular side [17], consistent with exper-
imental data for other GPCRs [38^40]. In contrast, the TMH
2 Asp to Asn mutant showed a smaller conformational
change, in an opposite direction, that may not facilitate cou-
pling to the G proteins [17].
While D114(2.50)N mutation did not a¡ect binding a⁄nity
of diprenorphine and naloxone signi¢cantly, it dramatically
decreased the a⁄nity of CTAP. Notably, the a⁄nity of
CTAP was restored to a level similar to that of the wild-
type by the combined D114(2.50)N-N332(7.49)D mutation.
The distinct structural feature of CTAP may contribute to
this di¡erence. Naloxone and diprenorphine have the epoxy-
morphinan structure shared by many opioid ligands, whereas
CTAP is a peptide with the sequence of D-Phe-Cys-Tyr-D-
Trp-Arg-Thr-Pen-Thr-NH2. One possibility is that CTAP
may be more sensitive to the agonist conformation of the
receptor although it is an antagonist. Indeed, Hawkins et al.
[41] reported that the a⁄nity of CTOP for the W opioid re-
ceptor was reduced by metal ions and GTP in a manner
similar to e¡ects on high a⁄nity agonist binding. Since
CTOP is an analog of CTAP with ornithine at the ¢fth posi-
tion instead of arginine, it is likely that CTAP is similarly
a¡ected by GTP and metal ions.
We conclude that the interaction between Asp114 at posi-
tion 2.50 in TMH 2 and the Asn332 at position 7.49 in TMH
7 is important for structural and functional integrity of the W
opioid receptor. The present ¢ndings indicating the reciprocal
e¡ects of Asp114(2.50) and Asn332(7.49) of the W opioid re-
ceptor underscore the structural relationship of this receptor
to the family of GPCRs. The integrity of the interaction be-
tween these loci is found to be crucial for high a⁄nity ligand
binding and activation of W opioid receptors in a manner
consistent with current structural models and mechanistic in-
ferences from other GPCRs. This should have signi¢cant im-
pact on the ability to characterize the mechanistic details of W
opioid receptor function and ligand interaction in the broader
context o¡ered by work on the other GPCR systems.
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